Comments
Pharma major Dr Reddy’s Laboratories Ltd has launched Invista. It is a formulation of Dasatinib that is bioequivalent to the innovator brand.
Patent on Dasatinib is owned by Bristol-Myers-Squibb. The Indian patent has expired on April 12, 2020.
It is indicated for the treatment of chronic accelerated or myeloid or lymphoid blast phase and newly diagnosed in chronic phase adult patients with Chronic Myeloid Leukemia (CML) in India.
"The development and launch of Invista is a significant step forward in improving access to medicines at an affordable price for CML patients in India," M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories said in a release on Monday.
Hyderabad - based Dr Reddy’s Invista is available in strengths of 50, 70 and 100 mg tablets.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.